Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Agalsidase Beta
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluate the Safety and Efficacy of Fabagal® (Agalsidase Beta) in Patients With Fabry Disease
Details : Undisclosed
Product Name : Fabagal
Product Type : Enzyme
Upfront Cash : Inapplicable
October 12, 2023
Lead Product(s) : Agalsidase Beta
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Agalsidase Beta
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Recipient : Petrovax
Deal Size : Inapplicable
Deal Type : Inapplicable
Fabagal® for Fabry Disease Management is Now Available in Russia
Details : Fabagal (agalsidase-beta) is a recombinant analogue of human alpha-galactosidase A and is produced by recombinant DNA technology. It is approved for the treatment of fabry disease in adults and children from 8 years old.
Product Name : Fabagal
Product Type : Enzyme
Upfront Cash : Inapplicable
February 10, 2023
Lead Product(s) : Agalsidase Beta
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Recipient : Petrovax
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Imiglucerase
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Isu Abxis Expects 100% Exclusive Treatment for Gaucher Disease in Algeria
Details : Abcertin (Imiglucerase) is an orphan drug independently developed by Isu Abxis, is an Enzyme Replacement Therapy (ERT) treatment for Gaucher disease with the same ingredient name as Cerezyme.
Product Name : Abcertin
Product Type : Enzyme
Upfront Cash : Inapplicable
December 08, 2022
Lead Product(s) : Imiglucerase
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : YH003,Toripalimab
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Eucure Biopharma
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the agreement, ISU ABXIS will utilize the sequence of YH003, Biocytogen’s humanized agonistic anti-CD40 antibody currently in phase II clinical trials, to construct a few groups of tri-specific antibodies and develop cancer drugs for...
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
October 31, 2022
Lead Product(s) : YH003,Toripalimab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Eucure Biopharma
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Imiglucerase
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Isu Abxis, Ranked First for Two Consecutive Years in the Algerian Gaucher Disease Treatment Bidding
Details : Abcertin (Imiglucerase) is an orphan drug independently developed by Isu Abxis, is an Enzyme Replacement Therapy (ERT) treatment for Gaucher disease with the same ingredient name as Cerezyme.
Product Name : Abcertin
Product Type : Enzyme
Upfront Cash : Inapplicable
October 22, 2022
Lead Product(s) : Imiglucerase
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Agalsidase Beta
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Petrovax
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Petrovax gains access to Fabagal (agalsidase beta), indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency).
Product Name : Fabagal
Product Type : Enzyme
Upfront Cash : Undisclosed
January 26, 2022
Lead Product(s) : Agalsidase Beta
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Petrovax
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery
Recipient : Eucure Biopharma
Deal Size : Undisclosed
Deal Type : Partnership
Details : YH003 is a humanized IgG2 agonistic CD40 antibody. Whether used as a single agent or in combination with anti-PD-1 monoclonal antibody drugs, YH003 demonstrated strong anti-tumor effects against multiple tumor.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 11, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Recipient : Eucure Biopharma
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Abcertin
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase I Study to Compare Abcertin and EU-sourced Cerezyme® in Healthy Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
March 09, 2021
Lead Product(s) : Abcertin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
June 11, 2018
Lead Product(s) : ISU304
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Catalyst Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 14, 2017
Lead Product(s) : ISU304
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Catalyst Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable